NT_1170x120_1-11-18

Orkambi

Vertex’s Orkambi seen as breakthrough in treating cystic fibrosis

Vertex’s Orkambi seen as breakthrough in treating cystic fibrosis

BOSTON — The approval of Vertex Pharmaceuticals Inc.’s Orkambi (lumacaftor/ivacaftor) is being hailed as a big stride forward in the treatment of cystic fibrosis. The Food and Drug Administration announced its approval of the drug just before the holiday weekend. Vertex noted that the medication is the first to treat the underlying cause of cystic fibrosis in